drugset

drugset / Trial / NCT03093168

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

NCT03093168 ↗

Phase 1 Unknown 10 enrolled The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine First Affiliated Hospital of Wenzhou Medical University · collab Hrain Biotechnology Co., Ltd. · collab Shanghai Changzheng Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.

Timeline

Start: 2017-02-15
Primary completion: 2019-09
Completion: 2020-02

Publications

Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, Yan X, Zhang Q, Zhang M, Wang L, Hong R, Chang AH, Yu J, Fu S, Kong D, Li L, Wang Y, Li Z, Jiang H, Huang J, Liu Z, Su N, Wei G, Hu Y, Huang H. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023 Aug;202(3):517-524. doi: 10.1111/bjh.18873. Epub 2023 May 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	anti-BCMA:TCRζ-4-1-BB CAR-T cells	Cell therapy	—	—
Background	Cyclophosphamide	Other / unclassified	40 mg/kg	—
Background	Fludarabine	Small molecule	25 mg/m2	—

Indications